• acute pancreatitis
• chronic pancreatitis
• pancreatic cancer
• study group

• Wellcome Trust
• na Translational Medicine Foundation, the University of Pécs, the Semmelweis University, the Hungarian Scientific Research Fund (OTKA), the Wellcome Trust, the Hungarian Academy of Sciences, the Royal Society, the Hungarian Government, the European Union Coh

• Acute pancreatitis
• Clinical outcomes
• Fluid resuscitation
• Mortality
• Type of Fluids

• Humans
• Fluid Therapy/methods
• Pancreatitis/therapy
• Pancreatitis/mortality
• Resuscitation/methods
• Treatment Outcome
• Acute Disease
• Randomized Controlled Trials as Topic

• acute pancreatitis
• hypertriglyceridaemia
• lipase

• Hypertriglyceridaemic pancreatitis
• diabetic ketoacidosis
• myotonic dystrophy
• sodium-glucose cotransporter-2 inhibitor

The pancreas is a glandular organ that is responsible for the proper functioning of the digestive and endocrine systems, and therefore, it affects the condition of the entire body. Consequently, it is important to effectively diagnose and treat diseases of this organ. According to clinicians, pancreatitis—a common disease affecting the pancreas—is one of the most complicated and demanding diseases of the abdomen. The classification of pancreatitis is based on clinical, morphologic, and histologic criteria. Medical doctors distinguish, inter alia, acute pancreatitis (AP), the most common causes of which are gallstone migration and alcohol abuse. Effective diagnostic methods and the correct assessment of the severity of acute pancreatitis determine the selection of an appropriate treatment strategy and the prediction of the clinical course of the disease, thus preventing life-threatening complications and organ dysfunction or failure. This review collects and organizes recommendations and guidelines for the management of patients suffering from acute pancreatitis.

• Acute pancreatitis
• Epidemiology
• Hypertriglyceridemia
• Incidence
• Trajectory

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, mostly causing respiratory symptoms, is also known to affect the gastrointestinal tract. Several case reports hypothesize that SARS-CoV-2 could be an etiological factor in acute pancreatitis (AP).

To assess all the available evidence in the literature relating to coronavirus disease 2019 (COVID-19) and AP.

We performed a systematic review of the available literature on the topic. The systematic search was conducted on 15 May 2020 on MEDLINE, EMBASE, CENTRAL, Web of Science and Scopus with a search key using the terms “amylase,” “lipase,” “pancr*,” “COVID-19” and synonyms. Due to the low quality and poor comparability of the studies, a meta-analysis was not performed.

Six case reports and two retrospective cohorts were included, containing data on eleven COVID-19 patients with AP. Five patients had AP according to the Atlanta classification. Other publications did not provide sufficient information on the diagnostic criteria. Most cases were considered SARS-CoV-2-induced, while several established etiological factors were not investigated. We were able to identify other possible causes in most of them.

We strongly highlight the need for adherence to the guidelines during a diagnostic and etiological workup, which could alter therapy.

• Pancreas
• COVID-19
• Pancreatic involvement
• Pancreatitis
• Amylase
• Lipase

• Acute Disease
• Betacoronavirus/isolation & purification
• COVID-19
• COVID-19 Testing
• Clinical Laboratory Techniques/methods
• Clinical Laboratory Techniques/standards
• Coronavirus Infections/complications
• Coronavirus Infections/diagnosis
• Guideline Adherence
• Humans
• Pancreatitis/virology
• Pandemics
• Pneumonia, Viral/complications
• Pneumonia, Viral/diagnosis
• Practice Guidelines as Topic
• SARS-CoV-2

The main causes of acute pancreatitis (AP) are biliary disease, alcohol consumption, hypertriglyceridaemia (HTG) and endoscopic retrograde cholangiopancreatography (ERCP). The aim of this meta-analysis was to evaluate the effects of these aetiological factors on the severity and outcome of AP. Pubmed and Embase were searched between 01/01/2012 and 31/05/2020. Included articles involved adult alcoholic, biliary, HTG- or post-ERCP AP (PAP) patients. Primary outcome was severity, secondary outcomes were organ failures, intensive care unit admission, recurrence rate, pancreatic necrosis, mortality, length of hospital stay, pseudocyst, fluid collection and systematic inflammatory response syndrome. Data were analysed from 127 eligible studies. The risk for non-mild (moderately severe and severe) condition was the highest in HTG-induced AP (HTG-AP) followed by alcoholic AP (AAP), biliary AP (BAP) and PAP. Recurrence rate was significantly lower among BAP vs. HTG-AP or AAP patients (OR = 2.69 and 2.98, 95% CI 1.55–4.65 and 2.22–4.01, respectively). Mortality rate was significantly greater in HTG-AP vs. AAP or BAP (OR = 1.72 and 1.50, 95% CI 1.04–2.84 and 0.96–2.35, respectively), pancreatic necrosis occurred more frequently in AAP than BAP patients (OR = 1.58, 95% CI 1.08–2.30). Overall, there is a potential association between aetiology and the development and course of AP. HTG-AP is associated with the highest number of complications. Furthermore, AAP is likely to be more severe than BAP or PAP. Greater emphasis should be placed on determining aetiology on admission.

• Acid suppressing drug
• Acute pancreatitis
• Gastrointestinal bleeding
• Gastrointestinal infection
• Proton pump inhibitor

• Acute pancreatitis
• Etiology
• Incidence rate
• Recurrent acute pancreatitis
• Risk factor

Introduction: Translational science has gained prominence in medicine, but there is still much work to be done before scientific results are used optimally and incorporated into everyday health practice. As the main focus is still on generating new scientific data with financial resources primarily available for that purpose, other activities that are necessary in the transition from research to community benefit are considered less needy. The European Statistical Office of the European Commission has recently reported that 1.7 million people under 75 years of age died in Europe in 2016, with around 1.2 million of those deaths being avoidable through effective primary prevention and public health intervention. Therefore, Academia Europaea, one of the five Pan-European networks that form SAPEA (Science Advice for Policy by European Academies), a key element of the European Commission’s Scientific Advice Mechanism (SAM), has launched a project to develop a model to facilitate and accelerate the utilisation of scientific knowledge for public and community benefit. Methods: During the process, leaders in the field, including prominent basic and clinical researchers, editors-in-chief of high-impact journals publishing translational research articles, translational medicine (TM) centre leaders, media representatives, academics and university leaders, developed the TM cycle, a new model that we believe could significantly advance the development of TM. Results: This model focuses equally on the acquisition of new scientific results healthcare, understandable and digestible summation of results, and their communication to all participants. We have also renewed the definition in TM, identified challenges and recommended solutions. Conclusion: The authors, including senior officers of Academia Europaea, produced this document to serve as a basis for revising thinking on TM with the end result of enabling more efficient and cost-effective healthcare.

• communication
• healthcare
• interdisciplinary
• knowledge
• science
• translation
• translational medicine